



# Marksans Pharma Ltd.

Date: 30<sup>th</sup> May, 2023

**BSE Limited**  
Corporate Relation Department  
Phiroze Jeejeeboi Towers,  
Dalal Street,  
Mumbai – 400001.  
Scrip Code: 524404

**National Stock Exchange of India  
Limited**  
Listing Department  
Exchange Plaza, C-1, Block-G,  
Bandra-Kurla Complex,  
Bandra (East), Mumbai – 400051.  
Symbol: MARKSANS

**Sub: Disclosure of Related Party Transactions under Regulation 23(9) of SEBI  
(Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir,

Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith disclosure of related party transactions for the half year ended 31<sup>st</sup> March, 2023.

This is for your information and records.

Thanking you,

Yours faithfully  
**For Marksans Pharma Limited**

**HARSHAVAR** Digitally signed by  
**DHAN** HARSHAVARDHAN  
**PANIGRAHI** PANIGRAHI  
Date: 2023.05.30  
15:02:35 +05'30'

**Harshavardhan Panigrahi**  
**Company Secretary**

Encl: As above

CIN : L24110MH1992PLC066364

[www.marksanspharma.com](http://www.marksanspharma.com)



**Marksans Pharma Ltd.**

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,  
Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • Fax : +91-22 4001 2011  
E-mail: [info@marksanspharma.com](mailto:info@marksanspharma.com)

## Disclosure of related party transactions for the half year ended 31<sup>st</sup> March 2023

(Rs. in Millions)

Sr. No	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments				
	Name	PAN (Refer Note 1)	Name	PAN (Refer Note 1)	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end usage)
1.	Marksans Pharma Limited		Nova Pharmaceuticals Australasia Pty Ltd		Subsidiary	Sale of goods	(Refer Note 2)	361.40	-	-	-	-	-	-	-	-		
2.	Marksans Pharma Limited		Bell, Sons and Co. (Druggists) Limited		Wholly-owned Subsidiary	Sale of goods	NA	240.68	-	-	-	-	-	-	-	-		
3.	Marksans Pharma Limited		Relonchem Limited		Wholly-owned Subsidiary	Sale of goods	NA	613.46	-	-	-	-	-	-	-	-		
4.	Marksans Pharma Limited		Time-Cap Laboratories Inc.		Wholly-owned Subsidiary	Sale of goods	NA	1477.82	-	-	-	-	-	-	-	-		
5.	Marksans Pharma Limited		Time-Cap Laboratories Inc.		Wholly-owned Subsidiary	Guarantee	NA	1.23	-	-	-	-	-	-	-	-		
6.	Marksans Pharma Limited		Nova Pharmaceuticals Australasia Pty Ltd		Subsidiary	Trade Receivables	-	-	382.77	435.12	-	-	-	-	-	-		
7.	Marksans Pharma Limited		Bell, Sons and Co. (Druggists) Limited		Wholly-owned Subsidiary	Trade Receivables	-	-	(43.29)	(98.83)	-	-	-	-	-	-		
8.	Marksans Pharma Limited		Relonchem Limited		Wholly-owned Subsidiary	Trade Receivables	-	-	(544.62)	(697.39)	-	-	-	-	-	-		
9.	Marksans Pharma Limited		Time-Cap Laboratories Inc.		Wholly-owned Subsidiary	Trade Receivables	-	-	2220.64	2151.1	-	-	-	-	-	-		
10.	Marksans Pharma Limited		Time-Cap Laboratories Inc.		Wholly-owned Subsidiary	Trade Payables	-	-	(0.05)	(0.05)	-	-	-	-	-	-		
12.	Marksans Pharma Limited		Mr. Mark Saldanha		Promoter & Key Managerial Personnel	Remuneration Paid	(Refer Note 3)	48.53	-	-	-	-	-	-	-	-		

13.	Marksans Pharma Limited	Mrs. Sandra Saldanha	Promoter & Key Managerial Personnel	Remuneration Paid	(Refer Note 3)	3.56	-	-	-	-	-	-	-	-	-	-	-
14.	Marksans Pharma Limited	Mr. Vardhman Vikramaditya Jain	Key Managerial Personnel	Remuneration Paid	(Refer Note 3)	6.87	-	-	-	-	-	-	-	-	-	-	-
15.	Marksans Pharma Limited	Mr. Jitendra Sharma	Key Managerial Personnel	Remuneration Paid	NA	6.33	-	-	-	-	-	-	-	-	-	-	-
16.	Marksans Pharma Limited	Mr. Harshavardhan Panigrahi	Key Managerial Personnel	Remuneration Paid	NA	1.34	-	-	-	-	-	-	-	-	-	-	-
17.	Marksans Pharma Limited	Mr. Abhinna Sundar Mohanty	Non-executive Director	Sitting Fees	NA	0.03	-	-	-	-	-	-	-	-	-	-	-
18.	Marksans Pharma Limited	Mr. Seetharama Raju Bhuddharaju	Non-executive Director	Sitting Fees	NA	0.03	-	-	-	-	-	-	-	-	-	-	-
19.	Marksans Pharma Limited	Mr. Digant Mahesh Parikh	Non-executive Director	Sitting Fees	NA	0.15	-	-	-	-	-	-	-	-	-	-	-
20.	Marksans Pharma Limited	Mrs. Meena Rani Surana	Non-executive Director	Sitting Fees	NA	0.03	-	-	-	-	-	-	-	-	-	-	-

Notes:

1. As per the Guidance Note for disclosure of related party transactions issued by the Stock Exchanges, the PAN details are not disclosed.
2. The transactions are within the limit of omnibus approval granted by the Audit Committee.
3. As per the approval of Board of Directors and/or Audit Committee in compliance with the provision of law.

*Ravi'shi*

